Neurological adverse effects caused by cytotoxic and targeted therapies.
Historically, body tissues with a high rate of cell turnover, such as the bone marrow, have been most susceptible to chemotherapy-induced damage. The widespread use of hematopoietic colony-stimulating factors, as well as the development of new agents, has led to improved outcomes in many types of cancer. As a consequence, neurotoxicity has become increasingly important as a cause of dose-limiting chemotherapy toxicity. An understanding of the neurologic complications of these new agents is crucial in order to prevent irreversible neurologic injury. Moreover, chemotherapy complications that require discontinuation of a potentially effective drug need to be distinguished from other causes of neurotoxicity including the tumor itself, paraneoplasia, radiation and surgery, which may require a different therapeutic strategy. We review the prevalence, prevention, and management of important and unusual neurotoxicities related to chemotherapy and targeted agents approved by the FDA since January 1999. These agents include DNA-damaging agents such as oxaliplatin and temozolomide, microtubule poisons like ixabepilone, proteasome inhibitors (bortezomib), and signal transduction inhibitors such as imatinib, sunitinib and bevacizumab.
Schiff
David
D
Department of Neurology, University of Virginia in Charlottesville, VA 22908-0432, USA. davidschiff@virginia.edu
Wen
Patrick Y
PY
van den Bent
Martin J
MJ
D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D001549:Benzamides; D000068258:Bevacizumab; D001897:Boronic Acids / Q000009:adverse effects; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives; D017277:Drug Approval; D034261:Epothilones / Q000009:adverse effects; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy*; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D009944:Organoplatinum Compounds / Q000009:adverse effects; D000077150:Oxaliplatin; D010879:Piperazines / Q000009:adverse effects; D011719:Pyrazines / Q000009:adverse effects; D011743:Pyrimidines / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D000077210:Sunitinib; D000077204:Temozolomide; D050257:Tubulin Modulators / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D001549:Benzamides; D001897:Boronic Acids; D034261:Epothilones; D007211:Indoles; D009944:Organoplatinum Compounds; D010879:Piperazines; D011719:Pyrazines; D011743:Pyrimidines; D011758:Pyrroles; D050257:Tubulin Modulators; D000077150:Oxaliplatin; D000068258:Bevacizumab; D000069286:Bortezomib; D003606:Dacarbazine; D000068877:Imatinib Mesylate; C430592:ixabepilone; D000077210:Sunitinib; D000077204:Temozolomide
J Clin Oncol. 2005 Nov 1;23(31):7794-803
16172456
J Clin Oncol. 2003 Apr 15;21(8):1637-47
12668652
Blood. 2002 Nov 1;100(9):3063-7
12384400
J Clin Oncol. 2009 Feb 10;27(5):740-5
19114704
J Clin Oncol. 2007 Aug 10;25(23):3559
17687168
J Clin Oncol. 2007 Sep 1;25(25):4028-9
17664456
J Clin Oncol. 2006 Oct 1;24(28):e48
17008686
Cancer. 2002 May 1;94(9):2434-40
12015768
Leuk Lymphoma. 2007 Oct;48(10):1922-30
17852710
Ann Oncol. 2007 Oct;18(10):1745-7
17890216
J Clin Oncol. 2006 Sep 20;24(27):4507-14
16940275
Neuro Oncol. 2008 Jun;10(3):355-60
18436627
J Clin Oncol. 1999 Oct;17(10):3110-6
10506606
J Neurooncol. 2003 Feb;61(3):203-7
12675312
Muscle Nerve. 2005 Jul;32(1):51-60
15880395
Leukemia. 2008 Jul;22(7):1419-27
18432260
Cancer Chemother Pharmacol. 2007 May;59(6):743-7
16953392
Eur Urol. 2008 Feb;53(2):376-81
17825982
J Clin Oncol. 2007 Oct 20;25(30):4722-9
17947719
J Clin Oncol. 2005 Jul 10;23(20):4553-60
16002847
J Invest Dermatol. 2002 Nov;119(5):1020-6
12445187
Neuro Oncol. 2008 Aug;10(4):624-30
18539884
Eur J Haematol. 2005 Mar;74(3):212-6
15693790
Semin Oncol. 2003 Aug;30(4 Suppl 15):5-13
14523789
Leuk Lymphoma. 2004 Aug;45(8):1633-6
15370217
J Neurol. 1999 May;246(5):339-46
10399863
Blood. 2007 Nov 15;110(10):3557-60
17690257
Clin Cancer Res. 2002 May;8(5):1038-44
12006516
J Clin Oncol. 2007 Aug 10;25(23):3407-14
17606974
Neurology. 2006 Dec 26;67(12):2253-5
17190958
Ann Oncol. 2007 Oct;18(10):1747-50
17890217
Br J Haematol. 2008 Jun;141(6):814-9
18410447
Dis Colon Rectum. 2008 Sep;51(9):1425-6
18470563
N Engl J Med. 2005 Jun 16;352(24):2487-98
15958804
J Clin Oncol. 2006 May 1;24(13):2084-91
16648510
N Engl J Med. 2002 Feb 28;346(9):645-52
11870241
Cancer. 2008 Jul 15;113(2):405-10
18484594
Curr Oncol. 2007 Jun;14(3):110-7
17593983
Oncologist. 2008 Jun;13(6):709-14
18586926
Ann Oncol. 2002 Apr;13(4):629-31
12056715
J Clin Oncol. 2005 Mar 1;23(7):1439-46
15735119
Blood. 2008 Sep 1;112(5):1638-45
18565853
Invest New Drugs. 2007 Apr;25(2):173-80
16983507
Clin Cancer Res. 2005 Aug 15;11(16):5981-3
16115942
J Support Oncol. 2003 Sep-Oct;1(3):194-205
15334875
Blood. 2007 Apr 1;109(7):2767-72
17148584
J Neurophysiol. 2001 May;85(5):2293-7
11353042
Clin Cancer Res. 1999 Mar;5(3):501-6
10100699
J Clin Oncol. 2005 May 20;23(15):3376-82
15908649
Leukemia. 2008 Jul;22(7):1343-53
18509355
J Clin Oncol. 2004 Jun 1;22(11):2184-91
15169807
Exp Neurol. 2007 Mar;204(1):317-25
17214983
Neurology. 2002 Dec 24;59(12):1872-5
12499476
Muscle Nerve. 2004 Mar;29(3):387-92
14981738
Arch Neurol. 2006 Oct;63(10):1475-8
17030665
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4055-61
15217938
J Clin Oncol. 2005 Sep 1;23(25):6019-26
16135470
J Clin Oncol. 2002 Aug 15;20(16):3478-83
12177109
J Clin Oncol. 2007 Aug 10;25(23):3415-20
17606972
J Clin Oncol. 2006 Jul 1;24(19):3113-20
16754936
Eur J Haematol. 2004 Jun;72(6):403-9
15128418
N Engl J Med. 2008 Jun 19;358(25):2746-7
18565874
Ann Pharmacother. 2005 Jan;39(1):128-35
15590869
N Engl J Med. 2006 Mar 2;354(9):980-2; discussion 980-2
16510760
Pediatr Blood Cancer. 2008 Mar;50(3):699-700
16991134
Neurology. 2007 Aug 7;69(6):573-81
17679676
Oncologist. 2001;6 Suppl 4:24-8
11585971
Neurology. 2004 Jun 22;62(12):2291-3
15210898
Clin Cancer Res. 2006 Aug 15;12(16):4899-907
16914578
Clin Cancer Res. 2007 Dec 1;13(23):7101-6
18056189
Blood. 2007 Apr 15;109(8):3214-8
17209054
J Clin Oncol. 2007 Mar 20;25(9):1082-8
17261851
J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3543
12972536
Neuro Oncol. 2007 Apr;9(2):145-60
17293590
Br J Haematol. 2006 Mar;132(5):584-93
16445831
Neurology. 2004 Aug 10;63(3):535-7
15304589
Eur J Cancer. 2006 Sep;42(14):2318-25
16899362
N Engl J Med. 2006 Mar 2;354(9):980-2; discussion 980-2
16514715
J Clin Oncol. 2002 Apr 1;20(7):1767-74
11919233
J Clin Oncol. 2008 May 1;26(13):2192-7
18445844
Leukemia. 2008 Dec;22(12):2247-56
18769451
Neurology. 2004 Jun 22;62(12):2288-90
15210897
Nat Rev Cancer. 2004 May;4(5):349-60
15122206